A Study of the Safety, Tolerability, Microbial Kinetics and Effect on Urinary Oxalate Excretion of FB-001 in Healthy Volunteers Fed a High Oxalate/Low Calcium Diet and in Patients With Enteric Hyperoxaluria
Latest Information Update: 27 Jan 2023
At a glance
- Drugs FB-001-Federation-Bio (Primary)
- Indications Hyperoxaluria
- Focus Adverse reactions; First in man
- Sponsors Federation Bio
Most Recent Events
- 15 Dec 2022 New trial record
- 08 Dec 2022 According to a Federation Bio media release, results of the trial will inform the design of a future Phase 2 trial.
- 08 Dec 2022 According to a Federation Bio media release, interim results from the part 1 phase of the study is anticipated in mid-2023.